CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
MK-3475drug
Likely dose
MK-3475 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04098068
NCT04098068Phase 2Completed
CompareCT.gov

Phase 2 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Sep 20, 2019·Updated Mar 30, 2025

In Brief

A Phase 2 clinical trial evaluating MK-3475 for High Tumor Mutation Burden and 2 related conditions. Completed, enrolled 12 participants across 3 sites.

Detailed Summary

This study will be looking at whether MK-3475 (pembrolizumab) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite Unstable) negative cancer with a mutator phenotype.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable)
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 20, 2019
Enrollment StartJan 25, 2018
Primary CompletionMay 15, 2022
Study CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.8 years ago

Interventions

MK-3475drug

MK-3475 (pembrolizumab) 200 mg flat dose every 21 days